ArticleAmerican journal of respiratory and critical care medicine2017
Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma.
Article in American journal of respiratory and critical care medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01430403 (Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations), which is not on this map. Cited by 122 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations (ICAC-20)
Who cites it
122 citing papers in PubMed, 3 syntheses or guidelines pooled it, 248 citations in OpenAlex.
- Prevalence of respiratory viruses in stable and acute asthma: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Safety and efficacy of omalizumab in children aged 6 to 11 years with asthma: a systematic review and meta-analysis of randomized controlled trials.BMC pediatrics · 2026Pooled it
- Respiratory Virus Epidemiology Among US Infants With Severe Bronchiolitis: Analysis of 2 Multicenter, Multiyear Cohort Studies.The Pediatric infectious disease journal · 2019Pooled it
- COVID-19 Immunologic Antiviral Therapy With Omalizumab (CIAO)-a Randomized Controlled Clinical Trial.Open forum infectious diseases · 2024Trial
- Allergen Immunotherapy Enhances Airway Epithelial Antiviral Immunity in Patients with Allergic Asthma (VITAL Study): A Double-Blind Randomized Controlled Trial.American journal of respiratory and critical care medicine · 2023Trial
- Effect of vitamin D supplementation on total and allergen-specific IgE in children with asthma and low vitamin D levels.The Journal of allergy and clinical immunology · 2022Trial
- Understanding the asthmatic response to an experimental rhinovirus infection: Exploring the effects of blocking IgE.The Journal of allergy and clinical immunology · 2020Trial
- Update on Pediatric asthma management: Recent advances.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Review
- The rhinovirus puzzle: Linking virus and host factors to childhood asthma.The Journal of allergy and clinical immunology · 2026Review
- Biologic Use in Type 2 versus Non-Type 2 Asthma: Similarities, Differences, and Challenges.Journal of inflammation research · 2026Review
- Age-specific efficacy of biologics in severe asthma: a pediatric perspective.Frontiers in allergy · 2026Review
- Are we there yet? understanding interactions between respiratory viral infections, atopy, and the microbiome.Frontiers in allergy · 2026Review
- Control first, tolerance second: biologics as enablers of allergen immunotherapy in severe allergic asthma.Frontiers in allergy · 2026Review
- A functional cell model using basophil activation test to study molecular mechanisms and biomarkers of response to omalizumab treatment in patients with asthma.Frontiers in immunology · 2026Article
- Neighborhood disadvantage and the back-to-school epidemic of viral-associated asthma exacerbations.The Journal of allergy and clinical immunology · 2025Article
- Real-World Effectiveness of Omalizumab Treatment in Adult Asthma Patients.Yonsei medical journal · 2025Article
- Unraveling the mechanisms of virus-induced asthma exacerbation: epithelial injury, immune dysregulation, and novel interventions.Chinese medical journal pulmonary and critical care medicine · 2025Review
- Epidemiology and genotypic diversity of rhinovirus in school-age children with acute respiratory illnesses seeking medical care.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2025Article
- Genetic contributions to epigenetic-defined endotypes of allergic phenotypes in children.American journal of human genetics · 2025Article
- Frequent exacerbator-a novel endotype of pediatric asthma.The Journal of allergy and clinical immunology · 2025Review
62 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
19 authors at 12 institutions in 1 country.
Funding
Abstract
rationaleAllergic inflammation has been linked to increased susceptibility to viral illnesses, but it is unclear whether this association is causal.
objectivesTo test whether omalizumab treatment to reduce IgE would shorten the frequency and duration of rhinovirus (RV) illnesses in children with allergic asthma.
methodsIn the PROSE (Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations) study, we examined children with allergic asthma (aged 6-17 yr; n = 478) from low-income census tracts in eight U.S. cities, and we analyzed virology for the groups randomized to treatment with guidelines-based asthma care (n = 89) or add-on omalizumab (n = 259). Weekly nasal mucus samples were analyzed for RVs, and respiratory symptoms and asthma exacerbations were recorded over a 90-day period during the fall seasons of 2012 or 2013. Adjusted illness rates (illnesses per sample) by treatment arm were calculated using Poisson regression. MEASUREMENTS AND MAIN
resultsRVs were detected in 97 (57%) of 171 exacerbation samples and 2,150 (36%) of 5,959 nonexacerbation samples (OR, 2.32; P < 0.001). Exacerbations were significantly associated with detection of rhinovirus C (OR, 2.85; P < 0.001) and rhinovirus A (OR, 2.92; P < 0.001), as well as, to a lesser extent, rhinovirus B (OR, 1.98; P = 0.019). Omalizumab decreased the duration of RV infection (11.2 d vs. 12.4 d; P = 0.03) and reduced peak RV shedding by 0.4 log units (95% confidence interval, -0.77 to -0.02; P = 0.04). Finally, omalizumab decreased the frequency of RV illnesses (risk ratio, 0.64; 95% confidence interval, 0.49-0.84).
conclusionsIn children with allergic asthma, treatment with omalizumab decreased the duration of RV infections, viral shedding, and the risk of RV illnesses. These findings provide direct evidence that blocking IgE decreases susceptibility to RV infections and illness. Clinical trial registered with www.clinicaltrials.gov (NCT01430403).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.